Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Operates in Pharma — Services. Per the activity note to the FY2024 annual report, the company provides promotional services related to medicines.
Subsidiary of Kerdzo Shezghuduli Pasukhismgeblobis Sazogadoeba AMERISOURCEBERGEN 60 INTERNATIONAL B.V. (100.0%)
| Ratio | 2022 | 2023 | 2024 |
|---|---|---|---|
| Margins | |||
| Gross Margin | 100.0% | 100.0% | 100.0% |
| EBITDA Margin | 14.9% | 10.1% | 17.9% |
| EBITDAR | 659 | 755 | 1,324 |
| EBITDAR Margin | 16.2% | 13.4% | 22.1% |
| EBIT Margin | 12.9% | 9.3% | 17.4% |
| Net Profit Margin | 10.3% | 7.6% | 16.3% |
| Operating Expense % of Sales | 85.1% | 89.9% | 82.1% |
| Returns | |||
| Return on Assets (ROA) | 53.8% | 51.1% | 38.6% |
| Return on Equity (ROE) | 55.3% | 52.4% | 54.2% |
| ROIC [EBIT / Invested Capital] | 143.6% | 282.4% | 225.0% |
| Leverage & debt balances | |||
| Debt-to-Assets | 0.0% | 0.0% | 0.0% |
| Debt-to-Equity | 0.00x | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.00x | 0.00x | 0.00x |
| Equity-to-Assets | 97.3% | 97.6% | 71.3% |
| Net Debt | -394 | -638 | -1,339 |
| Cash & Equivalents | 394 | 638 | 1,339 |
| Total Debt | N/A | N/A | N/A |
| Liquidity & working capital | |||
| Current Ratio | 21.71x | 33.15x | 3.32x |
| Quick Ratio | 21.71x | 33.15x | 3.32x |
| Cash Ratio | 18.77x | 31.64x | 1.85x |
| Total Current Assets | 455 | 669 | 2,410 |
| Total Current Liabilities | 21 | 20 | 725 |
| Inventory | N/A | N/A | N/A |
| Trade Receivables | 21 | N/A | 1,072 |
| Trade Payables | 3 | 20 | N/A |
| Net Working Capital | 434 | 649 | 1,685 |
| Net Working Capital % of Revenue | 10.7% | 11.5% | 28.2% |
| Trade Working Capital | 19 | -20 | 1,072 |
| Trade Working Capital % of Revenue | 0.5% | -0.4% | 17.9% |
| Change in Trade Working Capital | N/A | -39 | 1,092 |
| Turnover & efficiency | |||
| Inventory Turnover | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A |
| Receivables Turnover | 190.00x | N/A | 5.58x |
| Days Sales Outstanding (DSO) | 1.9 | N/A | 65.4 |
| Payables Turnover | N/A | N/A | N/A |
| Days Payable Outstanding (DPO) | N/A | N/A | N/A |
| Cash Conversion Cycle | 1.9 days | N/A | 65.4 days |
| Asset Turnover | 5.21x | 6.69x | 2.37x |
| Cash flow & dividends | |||
| Operating Cash Flow | 759 | 822 | N/A |
| Free Cash Flow (OCF − Capex proxy) | 476 | 683 | N/A |
| Cash Conversion (OCF / EBITDA) | 125.8% | 143.7% | N/A |
| Dividends Declared | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).